On July 30, 2024, Pfizer announced that they have made the difficult decision to discontinue the investigation of CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, for ambulatory patients with Duchenne muscular dystrophy.
To read their discontinuation update, please click here.
To read last month’s results announcement for CIFFREO, please click here.
